Arrowhead Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US04280A1007

SecurityARWR / Arrowhead Pharmaceuticals, Inc.
InstitutionONEQ - Fidelity Nasdaq Composite Index Tracking Stock
Latest Disclosed Ownership41,879 shares
Latest Disclosed Value $ 672,995
ONEQ - Fidelity Nasdaq Composite Index Tracking Stock reports 0.48% increase in ownership of ARWR / Arrowhead Pharmaceuticals, Inc.

On July 24, 2025 - ONEQ - Fidelity Nasdaq Composite Index Tracking Stock filed a NPORT-P form disclosing ownership of 41,879 shares of Arrowhead Pharmaceuticals, Inc. (US:ARWR) valued at $672,996 USD as of May 31, 2025. The entity filed a previous NPORT-P on April 25, 2025 disclosing 41,679 shares of Arrowhead Pharmaceuticals, Inc.. This represents a change in shares of 0.48% during the quarter. The current value of the position is $3,060,936 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-07-24 2025-05-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 41,879 200 0.48 673 -14.72 0.0089
2025-04-25 2025-02-28 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 41,679 1,080 2.66 788 -25.38 0.0106
2025-01-27 2024-11-30 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 40,599 -3,000 -6.88 1,057 1.73 0.0143
2024-10-29 2024-08-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 43,599 17,328 65.96 1,039 72.43 0.0154
2024-07-26 2024-05-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 26,271 325 1.25 603 -27.64 0.0096
2024-04-24 2024-02-29 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 25,946 403 1.58 833 53.79 0.0139
2024-01-24 2023-11-30 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 25,543 39 0.15 542 -23.15 0.0104
2023-10-27 2023-08-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 25,504 390 1.55 705 -18.52 0.0138
2023-07-26 2023-05-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 25,114 78 0.31 864 6.93 0.0186
2023-04-27 2023-02-28 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 25,036 585 2.39 809 2.67 0.0198
2023-01-26 2022-11-30 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 24,451 611 2.56 787 -16.81 0.0197
2022-10-26 2022-08-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 23,840 871 3.79 947 23.50 0.0237
2022-07-29 2022-05-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 22,969 676 3.03 766 -21.84 0.0195
2022-04-28 2022-02-28 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 22,293 338 1.54 981 -36.24 0.0227
2022-01-25 2021-11-30 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 21,955 559 2.61 1,538 7.03 0.0321
2021-10-26 2021-08-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 21,396 429 2.05 1,436 -5.65 0.0315
2021-07-22 2021-05-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 20,967 66 0.32 1,522 -8.53 0.0378
2021-04-23 2021-02-28 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 20,901 -3,028 -12.65 1,665 11.23 0.0434
2021-01-20 2020-11-30 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 23,929 2,810 13.31 1,496 67.71 0.0447
2020-10-16 2020-08-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 21,119 2,088 10.97 892 45.51 0.0275
2020-07-20 2020-05-31 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 19,031 567 3.07 614 -5.98 0.0240
2020-04-24 2020-02-29 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 18,464 -1,818 -8.96 653 -55.95 0.0291
2020-01-16 2019-11-30 NP ARROWHEAD PHARMACEUTICALS EC US04280A1007 20,282 20,282 1,481 0.0672
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.